Clinical trials: sponsored by C. R. Bard
Kidney Failure, Chronic, Hemodialysis Complication
The Pristine Post-Market Study
This is a prospective, multi-center, single-arm study designed to assess the safety and performance of the Pristine™ Long-Term Hemodialysis Catheter.
- Conditions
- Kidney Failure, Chronic, Hemodialysis Complication, Hemodialysis Catheter Infection, Hemodialysis Access Failure
- Trial name
- NCT05228132
- Testing
- Pristine™ Long-Term Hemodialysis Catheter
- Where
- 6 sites in United States
- Volunteers
- 142 people
- Sponsor
- C. R. Bard
Peripheral Arterial Disease, Peripheral Vascular Diseases
Real World Registry Assessing the Clinical Use of the Bard UltraScore Forced Focus PTA Balloon
The objective of this study is to assess the clinical use of the Bard® UltraScore™ Focused Force PTA balloon in a heterogeneous patient population in a real world, on-label clinical application.
- Conditions
- Peripheral Arterial Disease, Peripheral Vascular Diseases, Arterial Occlusive Diseases
- Trial name
- NCT03193619
- Testing
- PTA (UltraScore Focused Force PTA Balloon)
- Where
- 31 sites in United States
- Volunteers
- 350 people
- Sponsor
- C. R. Bard
Fever, Ischemic Stroke
Impact of Fever Prevention in Brain Injured Patients
This study will assess the impact of fever prevention on fever burden and short- and long-term neurologic outcomes in brain injured patients.
- Conditions
- Fever, Ischemic Stroke, Intracerebral Hemorrhage, Subarachnoid Hemorrhage
- Trial name
- INTREPID (NCT02996266)
- Testing
- Targeted Temperature Management, Standard Care
- Where
- 40 sites in United States, Australia and 4 more
- Volunteers
- 686 people
- Sponsor
- C. R. Bard
Embolization, Therapeutic
Caterpillar™ Arterial Embolization Device Post-Market Study
The primary objective of this study is to evaluate the performance and safety of the Caterpillar™ Arterial Embolization Device when used for arterial embolization in the peripheral vasculature in a real world, on-label…
- Trial name
- MONARCH (NCT04244370)
- Testing
- Caterpillar™ Arterial Embolization Device
- Where
- 11 sites in United States
- Volunteers
- 50 people
- Sponsor
- C. R. Bard
Superficial Musculoaponeurotic System (SMAS) Procedure
GalaFlex Mesh in Facelift
In this post market study a resorbable mesh (GalaFLEX) will be used to reinforce the lifted and imbricated SMAS along the suture lines and spread the load of the SMAS along a greater surface area.
- Trial name
- NCT02053831
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- C. R. Bard
Ptotic Breast
Use of GalaFlex in Ptotic Breast
This study is to assess the physician preference in the clinical performance of the GalaFLEX mesh in soft tissue reinforcement during elective (cosmetic) plastic surgery to the breast, in particular the breast lift mastopexy and…
- Trial name
- NCT02081157
- Testing
- GalaFlex Mesh
- Volunteers
- 69 people
- Sponsor
- C. R. Bard
Critical Limb Ischemia
Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia
This study will compare the effectiveness of best available surgical treatment with best available endovascular treatment in adults with critical limb ischemia (CLI) who are eligible for both treatment options.
- Trial name
- BEST-CLI (NCT02060630)
- Testing
- Open surgical revascularization, Endovascular revascularization
- Where
- 161 sites in United States, Canada and 3 more
- Volunteers
- 1,843 people
- Sponsor
- Carelon Research
Peripheral Arterial Disease, Peripheral Vascular Disease
Peripheral Registry of Endovascular Clinical Outcomes "The PRIME Registry"
The PRIME Registry is a multi-center, observational study designed to evaluate immediate and long-term outcomes (36 months) of endovascular revascularization in patients with critical limb ischemia (CLI) and advanced peripheral…
- Conditions
- Peripheral Arterial Disease, Peripheral Vascular Disease, Critical Limb Ischemia
- Trial name
- PRIME (NCT02786173)
- Where
- 6 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Metro Health, Michigan
Arteriovenous Fistula
Lutonix® Global AV Registry Investigating Lutonix Drug Coated Balloon for Treatment of Native and Synthetic AV Fistulae
The purpose of this Registry is to enroll patients presenting with clinical and hemodynamic abnormalities in native or synthetic (grafts) arteriovenous (AV) fistulae located in the arm.
- Trial name
- AVR (NCT02746159)
- Testing
- Lutonix 035 Drug Coated Balloon PTA Catheter, Model 9004
- Where
- 26 sites in Austria, France and 11 more
- Volunteers
- 320 people
- Sponsor
- C. R. Bard
Ventral Hernia
Comparative Study of Biologic Mesh Versus Repair With Component Separation.
The purpose of this study is to compare open abdominal incisional hernia repair using XenMATRIX biologic mesh versus repair with their own tissue.
- Trial name
- Davol (NCT01295125)
- Testing
- XenMATRIX mesh, Open abdominal ventral hernia repair
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Prostate Cancer
The Implantation Under Echography of Fiducial Markers in the Intraprostatic Lesion and Prostate
Implantation of fiducial markers in the prostate and daily check of the positioning during radiotherapy based on the implanted fiducial markers
- Trial name
- NCT00841685
- Testing
- Goldlock, Visicoil smallest size, Visicoil larger size
- Where
- Belgium
- Volunteers
- 25 people
- Sponsor
- University Hospital, Ghent
Vascular Diseases, Peripheral
FLUENCY® PLUS in the Treatment of Peripheral Artery Disease
This is a retrospective, multi-center study to assess the safety and performance by proactively reviewing pre-existing medical records and imaging of patients who had previous placement of FLUENCY® PLUS Vascular Stent Graft in…
- Trial name
- NCT04765566
- Testing
- Endovascular revascularization of peripheral arteries
- Where
- 6 sites in Germany, Poland
- Volunteers
- 146 people
- Sponsor
- C. R. Bard
Angioplasty, Stenosis of Arteriovenous Fistula
Paclitaxel-coated Balloon Angioplasty Versus Standard Angioplasty for the Treatment of Stenosis of Arteriovenous Fistula
The primary objective of this double-blind study is to compare the frequency of primary patency at 6 months in patients with stenosis of arteriovenous fistula (AVF) treated either by conventional angioplasty + angioplasty with…
- Trial name
- ABISS (NCT02753998)
- Testing
- Additional angioplasty with paclitaxel-coated balloon, Conventional angioplasty
- Where
- France
- Volunteers
- 145 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Critical Limb Ischemia
Lutonix DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries
To assess the safety and efficacy of the Lutonix Drug Coated Balloon (DCB) for treatment of stenosis or occlusion of native below-the-knee arteries.
- Trial name
- NCT01870401
- Testing
- Lutonix DCB, Uncoated PTA Catheter
- Where
- 51 sites in United States, Austria and 6 more
- Volunteers
- 442 people
- Sponsor
- C. R. Bard
Plastic Surgery, Reconstructive Surgery
STARS-R Registry: Retrospective Analysis of Poly-4-hydroxybutyrate (P4HB) Scaffold Use
This is a retrospective chart review performed at multiple clinics aimed at providing real-world evidence of the use and safety of the P4HB scaffold.
- Trial name
- NCT04195854
- Testing
- P4HB product
- Where
- 10 sites in United States
- Volunteers
- 1,183 people
- Sponsor
- C. R. Bard
Stenosis, Restenosis
Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft
The objective of this study is to assess the safety and effectiveness of the COVERA™ Vascular Covered Stent for the treatment of stenotic lesions in the upper extremity venous outflow of the Arteriovenous (AV) access circuit.
- Trial name
- AVeNEW (NCT02649946)
- Testing
- Covera Vascular Covered Stent following PTA, Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon
- Where
- 24 sites in United States, Australia and 6 more
- Volunteers
- 280 people
- Sponsor
- C. R. Bard
Incisional Hernia
Xen Matrix™ AB Surgical Graft in Ventral or Incisional Midline Hernias
This study aims to prospectively explore the use of XenMatrix™ AB Surgical Graft for ventral or incisional midline hernia repair in patients across all wound classes ("All Comers") through 24 months post repair.
- Trial name
- NCT02691962
- Testing
- Xen Matrix AB
- Where
- 11 sites in United States
- Volunteers
- 75 people
- Sponsor
- C. R. Bard
Indication for Peripheral Intravenous Catheterization, Atrial Flutter
SHERLOCK 3CG™ Diamond Tip Confirmation System
This study is a single-arm, prospective, multi-center study to assess clinical performance of the SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) with MODUS II software for confirming correct tip position of peripherally…
- Conditions
- Indication for Peripheral Intravenous Catheterization, Atrial Flutter, Premature Atrial Contraction, Premature Ventricular Contraction
- Trial name
- MODUS II (NCT03288766)
- Testing
- PICC placement with SHERLOCK 3CG™ Diamond TCS with MODUS II software
- Where
- 8 sites in United States, Australia
- Volunteers
- 232 people
- Sponsor
- C. R. Bard
Pulmonary Embolism, Deep Vein Thrombosis
Predicting the Safety and Effectiveness of Inferior Vena Cava Filters
PRESERVE is a multi-center, prospective, open-label, non-randomized investigation of commercially available IVC filters from 6 manufacturers placed in subjects for the prevention of pulmonary embolism (PE).
- Trial name
- PRESERVE (NCT02381509)
- Testing
- IVC Filter
- Where
- 53 sites in United States
- Volunteers
- 1,428 people
- Sponsor
- Carelon Research
Lung Cancer, Lung Tumor
NeoMend ProGEL™ Pleural Air Leak Sealant Post-Approval Study
The purpose of this post approval study is to further characterize the safety profile of the ProGEL™ Pleural Air Leak Sealant in commercial use, with specific reference to long-term safety over 90 days of follow-up.
- Trial name
- NCT01394978
- Testing
- Control, ProGEL Pleural Air Leak Sealant with standard surgical closure, ProGEL Pleural Air Leak Sealant without standard surgical closure
- Where
- 18 sites in United States
- Volunteers
- 444 people
- Sponsor
- C. R. Bard